Pellicelli AM, Morrone A, Barbieri L, Andreoli A

Idioma: Ingles.
Referencias bibliográficas: 15
Paginas: 951-954
Archivo PDF: 145.39 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39: 620-7.

2. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661-9.

3. Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis C. Hepatogastroenterology 1997; 44: 525-8.

4. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci 1998; 43: 529-33.

5. Siegel LB, Eber BB. Porphyria cutanea tarda remission. Ann Intern Med 1994; 121: 308-9.

6. Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesion after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995; 22: 249-50.

7. Thevenot T, Bachmeyer C, Hammi R, Dumouchel P, Ducamp- Posak I, Cadranel JF. Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C. J Hepatol 2005; 42: 607-8.

8. Jessner W, Der-Petrossian M, Christiansen L, Maier H, Steindl-Munda P, Gangl A, Ferenci P. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology 2002; 36: 1301-2.

9. Frider B, Buonsante ME, Tiscornia J, Alessio A, Pellerano G. Development of porphyria cutanea tarda in a chronic hepatitis C patient with indetectable viremia under treatment with peg-interferon plus ribavirin. Acta Gastroenterol Latinoam 2006; 36: 38-41.

10. Sebastiani G, Vario A, Ferrari A, Pistis R, Noventa F, Alberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. J Viral Hep 2006; 13: 199-205.

11. Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 2008; 49: 702-10.

12. Lin TJ, Liao LY, Chou JM, Liu SO, Wang CK. Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients. Hepatogastroenterology 2009; 56: 1146-51.

13. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol 2011; 54: 173-81.

14. Sypniewski D, Jurzak M, Cholewa K, Gola J, Mazurek U, Wilczok T, et al. Changes in TNF-alpha mRNA levels in the peripheral blood of patients with chronic hepatitis C virus (HCV) infection during alpha-interferon and ribavirin therapy. Viral Immunol 2004; 17: 580-7.

15. Azim J, McCurdy H, Moseley RH. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. World J Gastroenterol 2008; 14: 5913-5.